{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:58:40Z","timestamp":1770145120819,"version":"3.49.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40291-021-00549-z","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T14:02:36Z","timestamp":1628258556000},"page":"735-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-8121","authenticated-orcid":false,"given":"Thiago Dominguez Crespo","family":"Hirata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-9399","authenticated-orcid":false,"given":"Carolina","family":"Dagli-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-2879","authenticated-orcid":false,"given":"Fabiana Dalla Vecchia","family":"Genvigir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-6204","authenticated-orcid":false,"given":"Volker Martin","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-5444","authenticated-orcid":false,"given":"Yitian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-7979","authenticated-orcid":false,"given":"Mario Hiroyuki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-5967","authenticated-orcid":false,"given":"Rosario Dominguez Crespo","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"issue":"12","key":"549_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s40262-019-00792-y","volume":"58","author":"J Terrier","year":"2019","unstructured":"Terrier J, Daali Y, Fontana P, Csajka C, Reny JL. Towards personalized antithrombotic treatments: focus on P2Y12 inhibitors and direct oral anticoagulants. Clin Pharmacokinet. 2019;58(12):1517\u201332. https:\/\/doi.org\/10.1007\/s40262-019-00792-y.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"549_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/1074248420923528","volume":"25","author":"F Luc\u00e0","year":"2020","unstructured":"Luc\u00e0 F, Giubilato S, Fusco SAD, Leone A, Poli S, Rao CM, Iorio A, Gelsomino S, Gabrielli D, Colivicchi F, De Luca L, Gulizia MM. The combination of oral anticoagulant and antiplatelet therapies: stay one step ahead. J Cardiovasc Pharmacol Ther. 2020;25(5):391\u20138. https:\/\/doi.org\/10.1177\/1074248420923528.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"9","key":"549_CR3","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139\u2013596. https:\/\/doi.org\/10.1161\/CIR.0000000000000757.","journal-title":"Circulation"},{"issue":"3","key":"549_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cll.2016.05.002","volume":"36","author":"CL Maier","year":"2016","unstructured":"Maier CL, Duncan A, Hill CE. Pharmacogenetics in oral antithrombotic therapy. Clin Lab Med. 2016;36(3):461\u201372. https:\/\/doi.org\/10.1016\/j.cll.2016.05.002.","journal-title":"Clin Lab Med"},{"issue":"13","key":"549_CR5","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2174\/1381612822666151208122845","volume":"22","author":"F Storelli","year":"2016","unstructured":"Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P. Pharmacogenomics of oral antithrombotic drugs. Curr Pharm Des. 2016;22(13):1933\u201349. https:\/\/doi.org\/10.2174\/1381612822666151208122845.","journal-title":"Curr Pharm Des"},{"issue":"Suppl 3","key":"549_CR6","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.21037\/cdt.2017.09.11","volume":"7","author":"DD Monie","year":"2017","unstructured":"Monie DD, DeLoughery EP. Pathogenesis of thrombosis: cellular and pharmacogenetic contributions. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S291\u20138. https:\/\/doi.org\/10.21037\/cdt.2017.09.11.","journal-title":"Cardiovasc Diagn Ther."},{"key":"549_CR7","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666201231124715","author":"V Conti","year":"2020","unstructured":"Conti V, Corbi G, Manzo V, Sellitto C, Iannello F, Esposito S, De Bellis E, Iannaccone T, Filippelli A. The role of pharmacogenetics for antithrombotic therapy management: new achievements and barriers yet to overcome. Curr Med Chem. 2020. https:\/\/doi.org\/10.2174\/0929867328666201231124715.","journal-title":"Curr Med Chem"},{"issue":"9","key":"549_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.117.310965","volume":"122","author":"DM Roden","year":"2018","unstructured":"Roden DM, Van Driest SL, Wells QS, Mosley JD, Denny JC, Peterson JF. Opportunities and challenges in cardiovascular pharmacogenomics: from discovery to implementation. Circ Res. 2018;122(9):1176\u201390. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310965.","journal-title":"Circ Res"},{"issue":"17","key":"549_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/eurheartj\/ehs481","volume":"34","author":"R Nieuwlaat","year":"2013","unstructured":"Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013;34(17):1262\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehs481.","journal-title":"Eur Heart J"},{"issue":"3 Suppl 3","key":"549_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5935\/abc.2013S009","volume":"101","author":"AM Lorga Filho","year":"2013","unstructured":"Lorga Filho AM, Azmus AD, Soeiro AM, Quadros AS, Avezum A Jr, Marques AC, Franci A, Manica AL, Volschan A, De Paola AA, Greco AI, Ferreira AC, Sousa AC, Pesaro AE, Sim\u00e3o AF, Lopes AS, Timerman A, Ramos AI, Alves BR, Caramelli B, Mendes BA, Polanczyk CA, Montenegro CE, Barbosa CJ, Serrano CV Jr, Melo CC, Pinho C, Moreira DA, Calderaro D, Gualandro DM, Armaganijan D, Machado Neto EA, Bocchi EA, Paiva EF, Stefanini E, Daico E, Evaristo EF, Silva EE, Fernandes F, Brito FS Jr, Bacal F, Ganem F, Gomes FL, Mattos FR, Moraes Neto FR, Tarasoutchi F, Darrieux FC, Feitosa GS, Fenelon G, Morais GR, Correa Filho H, Castro I, Gon\u00e7alves I Jr, Ati\u00e9 J, Souza Neto JD, Ferreira JF, Nicolau JC, Faria Neto JR, Annichino-Bizzacchi JM, Zimerman LI, Piegas LS, Pires LJ, Baracioli LM, Silva LB, Mattos LA, Lisboa LA, Magalh\u00e3es LP, Lopes MA, Montera MW, Figueiredo MJ, Malachias MV, Gaz MV, Andrade MD, Bacellar MS, Barbosa MR, Clausell NO, Dutra OP, Coelho OR, Yu PC, Lav\u00edtola PL, Lemos Neto PA, Andrade PB, Farsky PS, Franco RA, Kalil RA, Lopes RD, Esporcatte R, Heinisch RH, Kalil Filho R, Giraldez RR, Alves RC, Leite RE, Gagliardi RJ, Ramos RF, Montenegro ST, Accorsi TA, Jardim TS, Scudeler TL, Mois\u00e9s VA, Portal VL. Diretrizes brasileiras de antiagregantes plaquet\u00e1rios e anticoagulantes em cardiologia [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. Arq Bras Cardiol. 2013;101(3 Suppl 3):1\u201395. https:\/\/doi.org\/10.5935\/abc.2013S009.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"549_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5935\/abc.20190128","volume":"113","author":"CV Serrano Jr","year":"2019","unstructured":"Serrano CV Jr, Soeiro AM, Leal TCAT, Godoy LC, Biselli B, Hata LA, Martins EB, Abud-Manta ICK, Tavares CAM, Cardozo FAM, Oliveira MT Jr. Statement on antiplatelet agents and anticoagulants in cardiology\u20142019. Arq Bras Cardiol. 2019;113(1):111\u201334. https:\/\/doi.org\/10.5935\/abc.20190128.","journal-title":"Arq Bras Cardiol"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-pharmtox-010611-134633","volume":"52","author":"J Fareed","year":"2012","unstructured":"Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79\u201399. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010611-134633.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.26402\/jpp.2018.4.01","volume":"69","author":"J Miklosz","year":"2018","unstructured":"Miklosz J, Kalaska B, Mogielnicki A. Pharmacogenetic considerations of anticoagulant medication. J Physiol Pharmacol. 2018;69:4. https:\/\/doi.org\/10.26402\/jpp.2018.4.01.","journal-title":"J Physiol Pharmacol"},{"issue":"49","key":"549_CR14","doi-asserted-by":"publisher","first-page":"29238","DOI":"10.18632\/oncotarget.25579","volume":"9","author":"N Cullell","year":"2018","unstructured":"Cullell N, Carrera C, Mui\u00f1o E, Torres N, Krupinski J, Fernandez-Cadenas I. Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget. 2018;9(49):29238\u201358. https:\/\/doi.org\/10.18632\/oncotarget.25579.","journal-title":"Oncotarget"},{"issue":"1","key":"549_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/jpm11010037","volume":"11","author":"J Raymond","year":"2021","unstructured":"Raymond J, Imbert L, Cousin T, Duflot T, Varin R, Wils J, Lamoureux F. Pharmacogenetics of direct oral anticoagulants: a systematic review. J Pers Med. 2021;11(1):37. https:\/\/doi.org\/10.3390\/jpm11010037.","journal-title":"J Pers Med."},{"issue":"10","key":"549_CR16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1161\/STROKEAHA.118.020369","volume":"49","author":"S Ross","year":"2018","unstructured":"Ross S, Par\u00e9 G. Pharmacogenetics of stroke. Stroke. 2018;49(10):2541\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.118.020369.","journal-title":"Stroke"},{"issue":"1","key":"549_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/17425255.2015.976201","volume":"11","author":"G Suarez-Kurtz","year":"2015","unstructured":"Suarez-Kurtz G, Botton MR. Pharmacogenetics of coumarin anticoagulants in Brazilians. Expert Opin Drug Metab Toxicol. 2015;11(1):67\u201379. https:\/\/doi.org\/10.1517\/17425255.2015.976201.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"549_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.drudis.2016.09.015","volume":"22","author":"A Isvoran","year":"2017","unstructured":"Isvoran A, Louet M, Vladoiu DL, Craciun D, Loriot MA, Villoutreix BO, Miteva MA. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22(2):366\u201376. https:\/\/doi.org\/10.1016\/j.drudis.2016.09.015.","journal-title":"Drug Discov Today"},{"issue":"1","key":"549_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00228-007-0385-2","volume":"64","author":"MV Lima","year":"2008","unstructured":"Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol. 2008;64(1):9\u201315. https:\/\/doi.org\/10.1007\/s00228-007-0385-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"549_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/clpt.2008.166","volume":"84","author":"JA Perini","year":"2008","unstructured":"Perini JA, Struchiner CJ, Silva-Assun\u00e7\u00e3o E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther. 2008;84(6):722\u20138. https:\/\/doi.org\/10.1038\/clpt.2008.166.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"549_CR21","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/j.thromres.2010.06.008","volume":"126","author":"FA Orsi","year":"2010","unstructured":"Orsi FA, Annichino Bizzacchi JM, de Paula EV, Ozelo MC, Langley MR, Weck KE. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res. 2010;126(3):e206\u201310. https:\/\/doi.org\/10.1016\/j.thromres.2010.06.008.","journal-title":"Thromb Res"},{"issue":"3","key":"549_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2125.2011.03942.x","volume":"72","author":"MR Botton","year":"2011","unstructured":"Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol. 2011;72(3):442\u201350. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03942.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"549_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00228-012-1404-5","volume":"69","author":"PC Santos","year":"2013","unstructured":"Santos PC, Dinardo CL, Schettert IT, Soares RA, Kawabata-Yoshihara L, Bensenor IM, Krieger JE, Lotufo PA, Pereira AC. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol. 2013;69(4):789\u201397. https:\/\/doi.org\/10.1007\/s00228-012-1404-5.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"549_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40291-014-0121-4","volume":"18","author":"VC de Oliveira Almeida","year":"2014","unstructured":"de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. Mol Diagn Ther. 2014;18(6):675\u201383. https:\/\/doi.org\/10.1007\/s40291-014-0121-4.","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"549_CR25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2217\/pgs.15.48","volume":"16","author":"PC Santos","year":"2015","unstructured":"Santos PC, Marcatto LR, Duarte NE, Gadi Soares RA, Cassaro Strunz CM, Scanavacca M, Krieger JE, Pereira AC. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics. 2015;16(8):865\u201376. https:\/\/doi.org\/10.2217\/pgs.15.48.","journal-title":"Pharmacogenomics"},{"issue":"12","key":"549_CR26","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00228-018-2528-z","volume":"74","author":"LC Tavares","year":"2018","unstructured":"Tavares LC, Duarte NE, Marcatto LR, Soares RAG, Krieger JE, Pereira AC, Santos PCJL. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population. Eur J Clin Pharmacol. 2018;74(12):1555\u201366. https:\/\/doi.org\/10.1007\/s00228-018-2528-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"549_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41397-019-0091-3","volume":"20","author":"A de Oliveira Magalh\u00e3es Mour\u00e3o","year":"2020","unstructured":"de Oliveira Magalh\u00e3es Mour\u00e3o A, Braga Gomes K, Afonso Reis E, Pedra de Souza R, de Freitas Campos EI, Dias Ribeiro D, da Costa Rocha MO, Parreiras Martins MA. Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. Pharmacogenomics J. 2020;20(1):104\u201313. https:\/\/doi.org\/10.1038\/s41397-019-0091-3.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"549_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/cts.12854","volume":"14","author":"N El Rouby","year":"2021","unstructured":"El Rouby N, Rodrigues-Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site investigation of genetic determinants of warfarin dose variability in Latinos. Clin Transl Sci. 2021;14(1):268\u201376. https:\/\/doi.org\/10.1111\/cts.12854.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"549_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.18553\/jmcp.2014.20.4.376","volume":"20","author":"PC Santos","year":"2014","unstructured":"Santos PC, Soares RA, Strunz CM, Grinberg M, Ferreira JF, Cesar LA, Scanavacca M, Krieger JE, Pereira AC. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events. J Manag Care Spec Pharm. 2014;20(4):376\u201381. https:\/\/doi.org\/10.18553\/jmcp.2014.20.4.376.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"549_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40256-020-00401-5","volume":"20","author":"D Hamilton Sr","year":"2020","unstructured":"Hamilton D Sr, Nandkeolyar S, Lan H, Desai P, Evans J, Hauschild C, Choksi D, Abudayyeh I, Contractor T, Hilliard A. Amiodarone: a comprehensive guide for clinicians. Am J Cardiovasc Drugs. 2020;20(6):549\u201358. https:\/\/doi.org\/10.1007\/s40256-020-00401-5.","journal-title":"Am J Cardiovasc Drugs"},{"key":"549_CR31","doi-asserted-by":"publisher","unstructured":"Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, D\u00e1vila-Fajardo C, Rodrigues-Botton M, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltr\u00e1n L, Jim\u00e9nez-Varo E, Ca\u00f1adas-Garre M, Giontella A, Kringen MK, Haug KBF, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Gen\u00e7 E, \u00d6zer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Loriot MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van-der-Zee AH, Verhoef TI, de-Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C. Effect of CYP4F2, VKORC1, and CYP2C9 in influencing coumarin dose: A single-patient data meta-analysis in more than 15,000 individuals. Clin Pharmacol Ther. 2019;105(6):1477\u20131491. https:\/\/doi.org\/10.1002\/cpt.1323.","DOI":"10.1002\/cpt.1323"},{"issue":"8","key":"549_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00228-009-0651-6","volume":"65","author":"M Fuchshuber-Moraes","year":"2009","unstructured":"Fuchshuber-Moraes M, Perini JA, Rosskopf D, Suarez-Kurtz G. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol. 2009;65(8):789\u201393. https:\/\/doi.org\/10.1007\/s00228-009-0651-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"549_CR33","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2217\/PGS.15.73","volume":"16","author":"EJ Parra","year":"2015","unstructured":"Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MH, Suarez-Kurtz G. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 2015;16(11):1253\u201363. https:\/\/doi.org\/10.2217\/PGS.15.73.","journal-title":"Pharmacogenomics"},{"key":"549_CR34","doi-asserted-by":"publisher","unstructured":"da-Silveira MMBM, Melo LA, Gomes FMF, Andrade LJCBDR, Serur IP, Piscoya ICV, Gueiros RM, Palmeira-do OK, de-Lima RE, Brasileiro VAE, Vasconcelos LRS, Sobral-Filho DC. Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. Appl Clin Genet. 2019;12:151\u2013159. https:\/\/doi.org\/10.2147\/TACG.S197316.","DOI":"10.2147\/TACG.S197316"},{"issue":"1 suppl 2","key":"549_CR35","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-GMB-2019-0025","volume":"43","author":"MR Botton","year":"2020","unstructured":"Botton MR, Viola PP, Meireles MR, Bruxel EM, Zuchinali P, Bandinelli E, Rohde LE, Leiria TLL, Salamoni JYY, Garbin AP, Hutz MH. Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genet Mol Biol. 2020;43(1 suppl 2): e20190025. https:\/\/doi.org\/10.1590\/1678-4685-GMB-2019-0025.","journal-title":"Genet Mol Biol"},{"issue":"34","key":"549_CR36","doi-asserted-by":"publisher","first-page":"54194","DOI":"10.18632\/oncotarget.10944","volume":"7","author":"LR Marcatto","year":"2016","unstructured":"Marcatto LR, Sacilotto L, Darrieux FC, Hachul DT, Scanavacca MI, Krieger JE, Pereira AC, Santos PC. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. Oncotarget. 2016;7(34):54194\u20139. https:\/\/doi.org\/10.18632\/oncotarget.10944.","journal-title":"Oncotarget"},{"issue":"2","key":"549_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00228-019-02772-4","volume":"76","author":"MFS Praxedes","year":"2020","unstructured":"Praxedes MFS, Martins MAP, Mour\u00e3o AOM, Gomes KB, Reis EA, Souza RP, Campos EIF, Ribeiro DD, Rocha MOC. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. Eur J Clin Pharmacol. 2020;76(2):199\u2013209. https:\/\/doi.org\/10.1007\/s00228-019-02772-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"549_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.111.184721","volume":"340","author":"SM Bratton","year":"2012","unstructured":"Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2012;340(1):46\u201355. https:\/\/doi.org\/10.1124\/jpet.111.184721.","journal-title":"J Pharmacol Exp Ther"},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2021.1876661","volume":"2","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi I. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol. 2021;2:1\u201328. https:\/\/doi.org\/10.1080\/17425255.2021.1876661.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"549_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00439-020-02150-6","volume":"139","author":"Q Xiao","year":"2020","unstructured":"Xiao Q, Zhou Y, Lauschke VM. Ethnogeographic and inter-individual variability of human ABC transporters. Hum Genet. 2020;139(5):623\u201346. https:\/\/doi.org\/10.1007\/s00439-020-02150-6.","journal-title":"Hum Genet"},{"key":"549_CR41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fphar.2018.00542","volume":"9","author":"LC Tavares","year":"2018","unstructured":"Tavares LC, Marcatto LR, Soares RAG, Krieger JE, Pereira AC, Santos PCJL. Association Between ABCB1 polymorphism and stable warfarin dose requirements in Brazilian patients. Front Pharmacol. 2018;9:542. https:\/\/doi.org\/10.3389\/fphar.2018.00542.","journal-title":"Front Pharmacol"},{"issue":"7","key":"549_CR42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/pgs-2017-0207","volume":"19","author":"LC Tavares","year":"2018","unstructured":"Tavares LC, Marcatto LR, Santos PCJL. Genotype-guided warfarin therapy: current status. Pharmacogenomics. 2018;19(7):667\u201385. https:\/\/doi.org\/10.2217\/pgs-2017-0207.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"549_CR43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s11239-013-0947-3","volume":"37","author":"P Zuchinali","year":"2014","unstructured":"Zuchinali P, Souza GC, Aliti G, Botton MR, Goldraich L, Santos KG, Hutz MH, Bandinelli E, Rohde LE. Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. J Thromb Thrombolysis. 2014;37(3):338\u201344. https:\/\/doi.org\/10.1007\/s11239-013-0947-3.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"549_CR44","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1124\/mol.109.054833","volume":"75","author":"MG McDonald","year":"2009","unstructured":"McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75(6):1337\u201346. https:\/\/doi.org\/10.1124\/mol.109.054833.","journal-title":"Mol Pharmacol"},{"issue":"8","key":"549_CR45","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1111\/j.1538-7836.2005.01419.x","volume":"3","author":"DW Stafford","year":"2005","unstructured":"Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005;3(8):1873\u20138. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01419.x.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"549_CR46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2165\/00003088-200645120-00004","volume":"45","author":"S Lal","year":"2006","unstructured":"Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet. 2006;45(12):1189\u2013200. https:\/\/doi.org\/10.2165\/00003088-200645120-00004.","journal-title":"Clin Pharmacokinet"},{"key":"549_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0083-6729(07)00005-2","volume":"78","author":"X Gong","year":"2008","unstructured":"Gong X, Gutala R, Jaiswal AK. Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85\u2013101. https:\/\/doi.org\/10.1016\/S0083-6729(07)00005-2.","journal-title":"Vitam Horm"},{"issue":"4","key":"549_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2009.307","volume":"87","author":"JA Perini","year":"2010","unstructured":"Perini JA, Struchiner CJ, Silva-Assun\u00e7\u00e3o E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther. 2010;87(4):417\u201320. https:\/\/doi.org\/10.1038\/clpt.2009.307.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"549_CR49","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2217\/pgs.12.164","volume":"13","author":"A Bress","year":"2012","unstructured":"Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012;13(16):1925\u201335. https:\/\/doi.org\/10.2217\/pgs.12.164.","journal-title":"Pharmacogenomics"},{"issue":"10","key":"549_CR50","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1194\/jlr.P086710","volume":"59","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, M\u00e4gi R, Milani L, Lauschke VM. Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. J Lipid Res. 2018;59(10):1987\u20132000. https:\/\/doi.org\/10.1194\/jlr.P086710.","journal-title":"J Lipid Res"},{"issue":"5","key":"549_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1755-5922.12186","volume":"34","author":"WY Yu","year":"2016","unstructured":"Yu WY, Sun X, Wadelius M, Huang L, Peng C, Ma WL, Yang GP. Influence of APOE gene polymorphism on interindividual and interethnic warfarin dosage requirement: a systematic review and meta-analysis. Cardiovasc Ther. 2016;34(5):297\u2013307. https:\/\/doi.org\/10.1111\/1755-5922.12186.","journal-title":"Cardiovasc Ther"},{"issue":"8","key":"549_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1592\/phco.31.8.785","volume":"31","author":"LH Cavallari","year":"2011","unstructured":"Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African\u2013American patients. Pharmacotherapy. 2011;31(8):785\u201392. https:\/\/doi.org\/10.1592\/phco.31.8.785.","journal-title":"Pharmacotherapy"},{"issue":"13","key":"549_CR53","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2217\/pgs-2016-0061","volume":"17","author":"N Eriksson","year":"2016","unstructured":"Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Par\u00e9 G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016;17(13):1425\u201339. https:\/\/doi.org\/10.2217\/pgs-2016-0061.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"549_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11239-017-1528-7","volume":"44","author":"E Vazquez-Garza","year":"2017","unstructured":"Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 2017;44(3):377\u201385. https:\/\/doi.org\/10.1007\/s11239-017-1528-7.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"549_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4172\/2153-0645.1000143","volume":"2015","author":"JB Borges","year":"2015","unstructured":"Borges JB, Hirata TDC, Cerda A, Fajardo CM, Cesar RCC, Fran\u00e7a JID, Santos JC, Wang H-TL, Castro LR, Sampaio MF, Hirata RDC, Hirata MH. Polymorphisms in genes encoding metalloproteinase 9 and lymphotoxin-alpha can influence warfarin treatment. J Pharmacogenom Pharmacoproteom. 2015;2015(6):143. https:\/\/doi.org\/10.4172\/2153-0645.1000143.","journal-title":"J Pharmacogenom Pharmacoproteom"},{"issue":"4","key":"549_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bcpt.12172","volume":"114","author":"MR Botton","year":"2014","unstructured":"Botton MR, Viola PP, Bandinelli E, Leiria TL, Rohde LE, Hutz MH. A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4\/5 and VKORC1 genes polymorphisms. Basic Clin Pharmacol Toxicol. 2014;114(4):323\u20139. https:\/\/doi.org\/10.1111\/bcpt.12172.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"549_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/FPC.0000000000000109","volume":"25","author":"MR Botton","year":"2015","unstructured":"Botton MR, Bandinelli E, Leiria TL, Rohde LE, Hutz MH. PPARA gene and phenprocoumon: a new predictor of response variability. Pharmacogenet Genomics. 2015;25(2):93\u20135. https:\/\/doi.org\/10.1097\/FPC.0000000000000109.","journal-title":"Pharmacogenet Genomics"},{"key":"549_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","volume":"136","author":"S Kersten","year":"2017","unstructured":"Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 2017;136:75\u201384. https:\/\/doi.org\/10.1016\/j.biochi.2016.12.019.","journal-title":"Biochimie"},{"issue":"6","key":"549_CR59","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/clpt.2011.336","volume":"91","author":"K Klein","year":"2012","unstructured":"Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, Zanger UM. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012;91(6):1044\u201352. https:\/\/doi.org\/10.1038\/clpt.2011.336.","journal-title":"Clin Pharmacol Ther"},{"key":"549_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2020.05.018","volume":"307","author":"H Nording","year":"2020","unstructured":"Nording H, Baron L, Langer HF. Platelets as therapeutic targets to prevent atherosclerosis. Atherosclerosis. 2020;307:97\u2013108. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.018.","journal-title":"Atherosclerosis"},{"issue":"5","key":"549_CR61","doi-asserted-by":"publisher","first-page":"568","DOI":"10.21037\/cdt.2018.07.01","volume":"8","author":"M Hamilos","year":"2018","unstructured":"Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc Diagn Ther. 2018;8(5):568\u201380. https:\/\/doi.org\/10.21037\/cdt.2018.07.01.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"1","key":"549_CR62","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.drudis.2018.09.021","volume":"24","author":"Y Baqi","year":"2019","unstructured":"Baqi Y, M\u00fcller CE. Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. Drug Discov Today. 2019;24(1):325\u201333. https:\/\/doi.org\/10.1016\/j.drudis.2018.09.021.","journal-title":"Drug Discov Today"},{"issue":"3","key":"549_CR63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","volume":"15","author":"JD McFadyen","year":"2018","unstructured":"McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15(3):181\u201391. https:\/\/doi.org\/10.1038\/nrcardio.2017.206.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"549_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/pgs-2019-0133","volume":"21","author":"M Ferreira","year":"2020","unstructured":"Ferreira M, Freitas-Silva M, Assis J, Pinto R, Nunes JP, Medeiros R. The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics. 2020;21(2):125\u201340. https:\/\/doi.org\/10.2217\/pgs-2019-0133.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"549_CR65","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/138920009790711814","volume":"10","author":"JA Ag\u00fandez","year":"2009","unstructured":"Ag\u00fandez JA, Mart\u00ednez C, P\u00e9rez-Sala D, Carballo M, Torres MJ, Garc\u00eda-Mart\u00edn E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009;10(9):998\u20131008. https:\/\/doi.org\/10.2174\/138920009790711814.","journal-title":"Curr Drug Metab"},{"issue":"4","key":"549_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/HCO.0000000000000640","volume":"34","author":"R Goel","year":"2019","unstructured":"Goel R, Baber U. Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. Curr Opin Cardiol. 2019;34(4):315\u201322. https:\/\/doi.org\/10.1097\/HCO.0000000000000640.","journal-title":"Curr Opin Cardiol"},{"issue":"10","key":"549_CR67","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.clinthera.2020.08.003","volume":"42","author":"PP Dobesh","year":"2020","unstructured":"Dobesh PP, Finks SW, Trujillo TC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. Clin Ther. 2020;42(10):2084\u201397. https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.003.","journal-title":"Clin Ther"},{"issue":"21","key":"549_CR68","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, D\u017eav\u00edk V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1908419.","journal-title":"N Engl J Med"},{"issue":"1","key":"549_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","volume":"141","author":"CN Floyd","year":"2014","unstructured":"Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141(1):69\u201378. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.08.005.","journal-title":"Pharmacol Ther"},{"key":"549_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.001","volume":"79","author":"D Sagris","year":"2020","unstructured":"Sagris D, Leventis I, Georgiopoulos G, Korompoki E, Makaritsis K, Vemmos K, Milionis H, Lip GYH, Ntaios G. Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. Eur J Intern Med. 2020;79:31\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2020.05.001.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"549_CR71","doi-asserted-by":"publisher","first-page":"474","DOI":"10.18433\/j3fc7f","volume":"18","author":"NJ Jalil","year":"2015","unstructured":"Jalil NJ, Bannur Z, Derahman A, Maskon O, Darinah N, Hamidi H, Gunasekaran OA, Rafizi M, Azreen NI, Kek TL, Salleh MZ. The implication of the polymorphisms of COX-1, UGT1A6, and CYP2C9 among cardiovascular disease (CVD) patients treated with aspirin. J Pharm Pharm Sci. 2015;18(3):474\u201383. https:\/\/doi.org\/10.18433\/j3fc7f.","journal-title":"J Pharm Pharm Sci"},{"issue":"11","key":"549_CR72","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/aps.2016.90","volume":"37","author":"LL Peng","year":"2016","unstructured":"Peng LL, Zhao YQ, Zhou ZY, Jin J, Zhao M, Chen XM, Chen LY, Cai YF, Li JL, Huang M. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin. 2016;37(11):1442\u20138. https:\/\/doi.org\/10.1038\/aps.2016.90.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"549_CR73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41397-020-00185-6","volume":"21","author":"M Forgerini","year":"2021","unstructured":"Forgerini M, Lucchetta RC, Urbano G, de Nadai TR, de Carvalho MP. Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review. Pharmacogenomics J. 2021;21(1):20\u201336. https:\/\/doi.org\/10.1038\/s41397-020-00185-6.","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"549_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078093","volume":"8","author":"Z Weng","year":"2013","unstructured":"Weng Z, Li X, Li Y, Lin J, Peng F, Niu W. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS ONE. 2013;8(11): e78093. https:\/\/doi.org\/10.1371\/journal.pone.0078093.","journal-title":"PLoS ONE"},{"issue":"15\u201316","key":"549_CR75","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.cca.2011.04.006","volume":"412","author":"LH Gon\u00e7alves","year":"2011","unstructured":"Gon\u00e7alves LH, Dusse LM, Fernandes AP, Gomes KB, S\u00f3ter MO, Alves MT, Rodrigues KF, Freitas FR, Komatsuzaki F, Sousa MO, Bosco AA, Pianett GA, Carvalho MD. Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake. Clin Chim Acta. 2011;412(15\u201316):1366\u201370. https:\/\/doi.org\/10.1016\/j.cca.2011.04.006.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"549_CR76","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MBC.0000000000000199","volume":"26","author":"RC Duarte","year":"2015","unstructured":"Duarte RC, Gon\u00e7alves LH, Campos FM, Filho OA, Alves MT, Fernandes AP, Borges KB, Dusse LM, Faria MC, Gon\u00e7alves GS, Bosco AA, Sandrim VC, Carvalho MG. Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 2015;26(2):123\u201330. https:\/\/doi.org\/10.1097\/MBC.0000000000000199.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"549_CR77","doi-asserted-by":"publisher","first-page":"891","DOI":"10.12669\/pjms.293.3497","volume":"29","author":"M Saboor","year":"2013","unstructured":"Saboor M, Ayub Q, Ilyas S, Moinuddin A. Platelet receptors; an instrumental of platelet physiology. Pak J Med Sci. 2013;29(3):891\u20136. https:\/\/doi.org\/10.12669\/pjms.293.3497.","journal-title":"Pak J Med Sci."},{"issue":"3","key":"549_CR78","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/bcp.12204","volume":"77","author":"CN Floyd","year":"2014","unstructured":"Floyd CN, Ferro A. The PlA1\/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446\u201357. https:\/\/doi.org\/10.1111\/bcp.12204.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"549_CR79","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1751-553X.2012.01420.x","volume":"34","author":"AA Timur","year":"2012","unstructured":"Timur AA, Murugesan G, Zhang L, Aung PP, Barnard J, Wang QK, Gaussem P, Silverstein RL, Bhatt DL, Kottke-Marchant K. P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol. 2012;34(5):473\u201383. https:\/\/doi.org\/10.1111\/j.1751-553X.2012.01420.x.","journal-title":"Int J Lab Hematol"},{"issue":"33","key":"549_CR80","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.2174\/138161212803251880","volume":"18","author":"SA O'Connor","year":"2012","unstructured":"O\u2019Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP. Pharmacogenetics of clopidogrel. Curr Pharm Des. 2012;18(33):5309\u201327. https:\/\/doi.org\/10.2174\/138161212803251880.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"549_CR81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","volume":"54","author":"XL Jiang","year":"2015","unstructured":"Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147\u201366. https:\/\/doi.org\/10.1007\/s40262-014-0230-6.","journal-title":"Clin Pharmacokinet"},{"key":"549_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12959-019-0197-5","volume":"17","author":"EMK Warlo","year":"2019","unstructured":"Warlo EMK, Arnesen H, Seljeflot I. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thromb J. 2019;17:11. https:\/\/doi.org\/10.1186\/s12959-019-0197-5.","journal-title":"Thromb J"},{"issue":"2","key":"549_CR83","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/cpt.1973","volume":"109","author":"MR Botton","year":"2021","unstructured":"Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Ag\u00fandez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352\u201366. https:\/\/doi.org\/10.1002\/cpt.1973.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"549_CR84","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","volume":"12","author":"NL Pereira","year":"2019","unstructured":"Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv. 2019;12(4): e007811. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.007811.","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"549_CR85","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.17219\/acem\/110322","volume":"28","author":"T W\u00f3jcik","year":"2019","unstructured":"W\u00f3jcik T, Szymkiewicz P, Wi\u015bniewski J, Lebioda A, Jonkisz A, Gamian A, Kuliczkowski W, \u015aciborski K, Mysiak A, Protasiewicz M. Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population. Adv Clin Exp Med. 2019;28(12):1621\u20136. https:\/\/doi.org\/10.17219\/acem\/110322.","journal-title":"Adv Clin Exp Med."},{"key":"549_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2233","author":"LS Br\u00e5ten","year":"2021","unstructured":"Br\u00e5ten LS, Haslemo T, Jukic MM, Ivanov M, Ingelman-Sundberg M, Molden E, Kringen MK. A novel CYP2C-haplotype associated with ultrarapid metabolism of escitalopram. Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.1002\/cpt.2233.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"549_CR87","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688\u2013700. https:\/\/doi.org\/10.1002\/cpt.690.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"549_CR88","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165660","volume":"50","author":"JF Marchini","year":"2017","unstructured":"Marchini JF, Pinto MR, Novaes GC, Badran AV, Pav\u00e3o RB, Figueiredo GL, Lago IM, Lima-Filho MO, Lemos DC, Tonani M, Antloga CM, Oliveira L, Lorenzi JC, Marin-Neto JA. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. Braz J Med Biol Res. 2017;50(1): e5660. https:\/\/doi.org\/10.1590\/1414-431X20165660.","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"549_CR89","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bcpt.12703","volume":"120","author":"AD Luchessi","year":"2017","unstructured":"Luchessi AD, Concheiro M, Germano JF, Silbiger VN, Bortolin RH, Cruz A, Quintela O, Brion M, Carracedo A, I\u00f1iguez A, Bravo M, L\u00f3pez-Rivadulla M, Hirata RD, Sousa AG, Hirata MH. ABCC3 polymorphisms and mRNA expression influence the concentration of a carboxylic acid metabolite in patients on clopidogrel and aspirin therapy. Basic Clin Pharmacol Toxicol. 2017;120(5):466\u201374. https:\/\/doi.org\/10.1111\/bcpt.12703.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"549_CR90","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/cdt.2018.05.06","volume":"8","author":"T Strisciuglio","year":"2018","unstructured":"Strisciuglio T, Franco D, Di Gioia G, De Biase C, Morisco C, Trimarco B, Barbato E. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovasc Diagn Ther. 2018;8(5):610\u201320. https:\/\/doi.org\/10.21037\/cdt.2018.05.06.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"8","key":"549_CR91","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/j.1476-5381.2012.01946.x","volume":"166","author":"V Ancrenaz","year":"2012","unstructured":"Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol. 2012;166(8):2362\u201370. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01946.x.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"549_CR92","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman HJ, Sch\u00f6mig E, van Werkum JW, Velder J, Hackeng CM, Hirschh\u00e4user C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17(1):110\u20136. https:\/\/doi.org\/10.1038\/nm.2281.","journal-title":"Nat Med"},{"issue":"4","key":"549_CR93","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2013.08.004","volume":"132","author":"X Li","year":"2013","unstructured":"Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Thromb Res. 2013;132(4):444\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2013.08.004.","journal-title":"Thromb Res"},{"key":"549_CR94","doi-asserted-by":"publisher","first-page":"3470145","DOI":"10.1155\/2019\/3470145","volume":"2019","author":"W Peng","year":"2019","unstructured":"Peng W, Shi X, Xu X, Lin Y. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome. Cardiovasc Ther. 2019;2019:3470145. https:\/\/doi.org\/10.1155\/2019\/3470145.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"549_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-019-0378-7","volume":"21","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Chen M, Zhang L, Zhao Q. The impact of cytochrome 450 and paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. BMC Pharmacol Toxicol. 2020;21(1):1. https:\/\/doi.org\/10.1186\/s40360-019-0378-7.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"549_CR96","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.thromres.2014.08.017","volume":"134","author":"JH Zhang","year":"2014","unstructured":"Zhang JH, Tang XF, Zhang Y, Wang J, Yao Y, Ma YL, Xu B, Gao RL, Gao Z, Chen J, Song L, Wu Y, Meng XM, Yuan JQ. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. Thromb Res. 2014;134(5):970\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2014.08.017.","journal-title":"Thromb Res"},{"issue":"5","key":"549_CR97","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamaneurol.2018.4775","volume":"76","author":"Y Pan","year":"2019","unstructured":"Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, Zhao X, Liu L, Wang D, Meng X, Wang Y. Clopidogrel in High-risk patients with acute nondisabling cerebrovascular events (CHANCE) investigators. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial. JAMA Neurol. 2019;76(5):552\u201360. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4775.","journal-title":"JAMA Neurol"},{"issue":"10","key":"549_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046366","volume":"7","author":"J Su","year":"2012","unstructured":"Su J, Xu J, Li X, Zhang H, Hu J, Fang R, Chen X. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS ONE. 2012;7(10): e46366. https:\/\/doi.org\/10.1371\/journal.pone.0046366.","journal-title":"PLoS ONE"},{"issue":"12","key":"549_CR99","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/14740338.2020.1836152","volume":"19","author":"M Biswas","year":"2020","unstructured":"Biswas M, Rahaman S, Biswas TK, Ibrahim B. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(12):1605\u201316. https:\/\/doi.org\/10.1080\/14740338.2020.1836152.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"549_CR100","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1124\/dmd.117.078329","volume":"46","author":"JZ Ji","year":"2018","unstructured":"Ji JZ, Tai T, Huang BB, Gu TT, Mi QY, Xie HG. Mrp3 transports clopidogrel acyl glucuronide from the hepatocytes into blood. Drug Metab Dispos. 2018;46(2):151\u20134. https:\/\/doi.org\/10.1124\/dmd.117.078329.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"549_CR101","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/17425255.2015.981152","volume":"11","author":"LW van der Schoor","year":"2015","unstructured":"van der Schoor LW, Verkade HJ, Kuipers F, Jonker JW. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol. 2015;11(2):273\u201393. https:\/\/doi.org\/10.1517\/17425255.2015.981152.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"549_CR102","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00008571-200403000-00003","volume":"14","author":"T Lang","year":"2004","unstructured":"Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger UM, Eichelbaum M, Fromm MF. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics. 2004;14(3):155\u201364. https:\/\/doi.org\/10.1097\/00008571-200403000-00003.","journal-title":"Pharmacogenetics"},{"issue":"8","key":"549_CR103","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/1440-1681.12118","volume":"40","author":"JJ Zou","year":"2013","unstructured":"Zou JJ, Fan HW, Chen SL, Tan J, He BS, Xie HG. Efffect of the ABCC3 -211C\/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2013;40(8):504\u20139. https:\/\/doi.org\/10.1111\/1440-1681.12118.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"8","key":"549_CR104","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/138920010794233521","volume":"11","author":"V Ancrenaz","year":"2010","unstructured":"Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab. 2010;11(8):667\u201377. https:\/\/doi.org\/10.2174\/138920010794233521.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"549_CR105","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/aps.2016.41","volume":"37","author":"R Liu","year":"2016","unstructured":"Liu R, Zhou ZY, Chen YB, Li JL, Yu WB, Chen XM, Zhao M, Zhao YQ, Cai YF, Jin J, Huang M. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin. 2016;37(7):882\u20138. https:\/\/doi.org\/10.1038\/aps.2016.41.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"549_CR106","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/1755-5922.12223","volume":"34","author":"HH Yang","year":"2016","unstructured":"Yang HH, Chen Y, Gao CY. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther. 2016;34(6):460\u20137. https:\/\/doi.org\/10.1111\/1755-5922.12223.","journal-title":"Cardiovasc Ther"},{"issue":"7","key":"549_CR107","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1076029616648408","volume":"23","author":"X Yi","year":"2017","unstructured":"Yi X, Wang Y, Lin J, Cheng W, Zhou Q, Wang C. Interaction of CYP2C19, P2Y12, and GPIIIa variants associates with efficacy of clopidogrel and adverse events on patients with ischemic stroke. Clin Appl Thromb Hemost. 2017;23(7):761\u20138. https:\/\/doi.org\/10.1177\/1076029616648408.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"549_CR108","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.amjcard.2020.03.019","volume":"125","author":"L Baldetti","year":"2020","unstructured":"Baldetti L, Melillo F, Moroni F, Gallone G, Pagnesi M, Venuti A, Beneduce A, Calvo F, Gramegna M, Godino C, D\u2019Ascenzo F, De Ferrari GM, Capodanno D, Cappelletti AM. Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome. Am J Cardiol. 2020;125(12):1815\u201322. https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.019.","journal-title":"Am J Cardiol"},{"issue":"1","key":"549_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1570161116666180206110657","volume":"17","author":"J M\u00e1chal","year":"2019","unstructured":"M\u00e1chal J, Hlinomaz O. Efficacy of P2Y12 receptor blockers after myocardial infarction and genetic variability of their metabolic pathways. Curr Vasc Pharmacol. 2019;17(1):35\u201340. https:\/\/doi.org\/10.2174\/1570161116666180206110657.","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"549_CR110","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.iccl.2016.08.010","volume":"6","author":"LH Cavallari","year":"2017","unstructured":"Cavallari LH, Obeng AO. Genetic determinants of P2Y12 inhibitors and clinical implications. Interv Cardiol Clin. 2017;6(1):141\u20139. https:\/\/doi.org\/10.1016\/j.iccl.2016.08.010.","journal-title":"Interv Cardiol Clin."},{"issue":"2","key":"549_CR111","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41397-020-00189-2","volume":"21","author":"C Valeria","year":"2021","unstructured":"Valeria C, Carmine S, Valentina M, Teresa I, Maria C, Martina T, Giancarlo A, Giovanna N, Graziamaria C, Amelia F. The need of a multicomponent guiding approach to personalize clopidogrel treatment. Pharmacogenomics J. 2021;21(2):116\u201327. https:\/\/doi.org\/10.1038\/s41397-020-00189-2.","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"549_CR112","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","volume":"5","author":"T Cuisset","year":"2012","unstructured":"Cuisset T, Loosveld M, Morange PE, Quilici J, Moro PJ, Saut N, Gaborit B, Castelli C, Beguin S, Grosdidier C, Fourcade L, Bonnet JL, Alessi MC. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv. 2012;5(12):1280\u20137. https:\/\/doi.org\/10.1016\/j.jcin.2012.07.015.","journal-title":"JACC Cardiovasc Interv"},{"key":"549_CR113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2018.11.013","volume":"173","author":"Z Liu","year":"2019","unstructured":"Liu Z, Xiang Q, Zhao X, Wang Z, Mu G, Xie Q, Zhou S, Chen S, Hu K, Xu J, Ma L, Cui Y. Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. Thromb Res. 2019;173:27\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2018.11.013.","journal-title":"Thromb Res"},{"issue":"10","key":"549_CR114","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2217\/pgs.13.108","volume":"14","author":"Q Xiang","year":"2013","unstructured":"Xiang Q, Cui Y, Zhao X, Zhao N. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics. 2013;14(10):1179\u201389. https:\/\/doi.org\/10.2217\/pgs.13.108.","journal-title":"Pharmacogenomics"},{"issue":"44","key":"549_CR115","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.2174\/1381612823666170817122043","volume":"23","author":"Q Xiang","year":"2017","unstructured":"Xiang Q, Zhou S, Lewis JP, Shuldiner AR, Ren G, Cui Y. Genetic variants of PEAR1 are associated with platelet function and antiplatelet drug efficacy: a systematic review and meta-analysis. Curr Pharm Des. 2017;23(44):6815\u201327. https:\/\/doi.org\/10.2174\/1381612823666170817122043.","journal-title":"Curr Pharm Des"},{"issue":"23","key":"549_CR116","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","volume":"128","author":"R Aungraheeta","year":"2016","unstructured":"Aungraheeta R, Conibear A, Butler M, Kelly E, Nylander S, Mumford A, Mundell SJ. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016;128(23):2717\u201328. https:\/\/doi.org\/10.1182\/blood-2016-03-707844.","journal-title":"Blood"},{"key":"549_CR117","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/TCRM.S152369","volume":"14","author":"MJ Kubisa","year":"2018","unstructured":"Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postu\u0142a M. Ticagrelor\u2014toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129\u201340. https:\/\/doi.org\/10.2147\/TCRM.S152369.","journal-title":"Ther Clin Risk Manag"},{"issue":"29","key":"549_CR118","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","volume":"36","author":"C Varenhorst","year":"2015","unstructured":"Varenhorst C, Eriksson N, Johansson \u00c5, Barratt BJ, Hagstr\u00f6m E, \u00c5kerblom A, Syv\u00e4nen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L. PLATO Investigators Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehv116.","journal-title":"Eur Heart J"},{"issue":"12","key":"549_CR119","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/00498254.2016.1271962","volume":"47","author":"M Li","year":"2017","unstructured":"Li M, Hu Y, Wen Z, Li H, Hu X, Zhang Y, Zhang Z, Xiao J, Tang J, Chen X. Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers. Xenobiotica. 2017;47(12):1130\u20138. https:\/\/doi.org\/10.1080\/00498254.2016.1271962.","journal-title":"Xenobiotica"},{"issue":"3","key":"549_CR120","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397\u2013404. https:\/\/doi.org\/10.1002\/cpt.668.","journal-title":"Clin Pharmacol Ther"},{"key":"549_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","volume":"11","author":"H Abdullah-Koolmees","year":"2021","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol. 2021;11: 595219. https:\/\/doi.org\/10.3389\/fphar.2020.595219.","journal-title":"Front Pharmacol"},{"issue":"5","key":"549_CR122","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/bcpt.13196","volume":"124","author":"F Rodrigues-Soares","year":"2019","unstructured":"Rodrigues-Soares F, Suarez-Kurtz G. Pharmacogenomics research and clinical implementation in Brazil. Basic Clin Pharmacol Toxicol. 2019;124(5):538\u201349. https:\/\/doi.org\/10.1111\/bcpt.13196.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"549_CR123","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.118.311963","volume":"39","author":"MD Klein","year":"2019","unstructured":"Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019;39(4):647\u201352. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311963.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"549_CR124","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/PGPM.S231475","volume":"13","author":"MN Gower","year":"2020","unstructured":"Gower MN, Ratner LR, Williams AK, Rossi JS, Stouffer GA, Lee CR. Clinical utility of CYP2C19 genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: A review of emerging evidence. Pharmgenomics Pers Med. 2020;13:239\u201352. https:\/\/doi.org\/10.2147\/PGPM.S231475.","journal-title":"Pharmgenomics Pers Med."},{"issue":"6","key":"549_CR125","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/1354750X.2019.1634764","volume":"24","author":"L Zheng","year":"2019","unstructured":"Zheng L, Yang C, Xiang L, Hao Z. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers. 2019;24(6):517\u201323. https:\/\/doi.org\/10.1080\/1354750X.2019.1634764.","journal-title":"Biomarkers"},{"issue":"3","key":"549_CR126","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner A. Clinical pharmacogenetics implementation consortium clinical pharmacogenetics implementation. Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317\u201323. https:\/\/doi.org\/10.1038\/clpt.2013.105.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"549_CR127","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2174\/1381612822666161226152529","volume":"23","author":"G Siasos","year":"2017","unstructured":"Siasos G, Zaromitidou M, Oikonomou E, Vavuranakis M, Tsigkou V, Papageorgiou N, Chaniotis D, Vrachatis DA, Stefanadis C, Papavassiliou AG, Tousoulis D. Genetics in the clinical decision of antiplatelet treatment. Curr Pharm Des. 2017;23(9):1307\u201314. https:\/\/doi.org\/10.2174\/1381612822666161226152529.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"549_CR128","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315. https:\/\/doi.org\/10.1093\/eurheartj\/ehv320.","journal-title":"Eur Heart J"},{"issue":"4","key":"549_CR129","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","volume":"39","author":"A Majithia","year":"2019","unstructured":"Majithia A, Bhatt DL. Novel antiplatelet therapies for atherothrombotic diseases. Arterioscler Thromb Vasc Biol. 2019;39(4):546\u201357. https:\/\/doi.org\/10.1161\/ATVBAHA.118.310955.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-021-00549-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T21:22:37Z","timestamp":1638048157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-021-00549-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40291-021-00549-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"12 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB and discloses consultancy work for Enginzyme AB. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Hirata TDC, Dagli-Hernandez C, and Hirata RDC: Conceived and planned the manuscript. Hirata TDC and Hirata RDC: Researched the information, interpreted the data, and drafted the manuscript. Dagli-Hernandez C, Genvigir FDV, VM Lauschke, Yitian Zhou, and Hirata MH: Critically reviewed the manuscript. All authors approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}